Non-small Cell Lung Cancer (NSCLC)Phase 1NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
A Phase 1 study testing RMC-5127, daraxonrasib and cetuximab in people with Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), run by Revolution Medicines, Inc. at 9 sites in United States.
Trial summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma
- What is being tested?
- RMC-5127, daraxonrasib and cetuximab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 574 participants
- Where
- 9 sitesUnited States
- Study dates
- 8 Jan 2026to Oct 2028
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
- Measurable per RECIST v1.1
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- Able to take oral medications.
Who cannot join
- Primary central nervous system (CNS) tumors
- Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors).
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to receiving study drug(s).
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
9 sites in 1 country
United States9 sites, 9 recruiting
- Recruiting
Johns Hopkins
Baltimore, Maryland, 21231
Clinical Trials Contact, phase1trials@jh.edu
- Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Kailene Sullivan, 617-632-3482, kailene_sullivan@dfci.harvard.edu
- Recruiting
NEXT - Dallas
Dallas, Texas, 75039
NEXT TXReferrels, 972-893-8800, NXT_TXReferrals@nextoncology.com
- Recruiting
NEXT - Virginia
Fairfax, Virginia, 22031
Paolo Umayam, 703-783-4546, pumayam@nextoncology.com
- Recruiting
START Midwest
Grand Rapids, Michigan, 49546
616-954-5554 ext. ext. 4, hopeteam@startresearch.com
- Recruiting
Yale Cancer Center
New Haven, Connecticut, 06511
Ingrid Palma, 203-833-1034, ingrid.palma@yale.edu
- Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016
Salman Punekar, 212-731-6228, salman.punekar@nyulangone.org
- Recruiting
NEXT
San Antonio, Texas, 78229
Jordan Georg, 210-580-9521, jgeorg@nextoncology.com
- Recruiting
START - San Antonio
San Antonio, Texas, 78229
HOPE Team, 210-593-5250, hopeteam@startresearch.com
About this study
Official title: Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Read the detailed description
This is an open-label, multicenter, Phase 1/1b study of RMC-5127 in adults with advanced KRAS G12V-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of three arms: RMC-5127 monotherapy arm, RMC-5127 plus daraxonrasib combination arm, and RMC-5127 plus cetuximab combination arm. All arms consist of two parts: Part 1- dose exploration and Part 2- dose expansion. Both parts of the monotherapy arm may include Food Effect Cohorts.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC
- Being tested
- RMC-5127, daraxonrasib, cetuximab
- Keywords
- Advanced Solid Tumors, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, Colorectal Cancer, CRC, Lung Cancer, Non-small Cell Lung Cancer, NSCLC, RAS, KRAS, RAS Mutation
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RMC-5127Drug
oral tablets
daraxonrasibDrug
oral tablets
cetuximabDrug
IV infusion
| Study group | Role | What they receive |
|---|---|---|
| Arm A: RMC-5127 Monotherapy | Experimental | Dose Escalation and Dose Expansion Receives: Drug: RMC-5127 |
| Arm B: RMC-5127 + Daraxonrasib Combination | Experimental | Dose Escalation and Dose Expansion Receives: Drug: RMC-5127; Drug: daraxonrasib |
| Arm C: RMC-5127 + Cetuximab Combination | Experimental | Dose Escalation and Dose Expansion Receives: Drug: RMC-5127; Drug: cetuximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with adverse events (AEs)
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Measured: Up to approximately 3 years
Changes in vital signs
Number of patients with changes from baseline in vital signs
Measured: Up to approximately 3 years
Changes in electrocardiogram (ECG) test values
Number of patients with changes from baseline in ECG test values
Measured: Up to approximately 3 years
Changes in clinical laboratory test values
Number of patients with changes from baseline in clinical laboratory test values
Measured: Up to approximately 3 years
Dose Limiting Toxicities
Number of patients with dose limiting toxicities
Measured: Up to 28 days
Secondary outcomes (7)
Cmax concentrations of RMC-5127 and daraxonrasib
Maximum blood concentration (Cmax) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and Cmax of daraxonrasib in combination with RMC-5127 over time as applicable
Measured: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Tmax concentration of RMC-5127 and daraxonrasib
Time to reach maximum blood concentration (Tmax) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and Tmax of daraxonrasib in combination with RMC-5127 over time as applicable
Measured: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
AUC concentrations of RMC-5127 and daraxonrasib
Area under the blood concentration time curve (AUC) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and AUC of daraxonrasib in combination with RMC-5127 over time as applicable
Measured: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Ratio of accumulation of RMC-5127
Ratio of accumulation of RMC-5127 from a single dose to steady state with repeated dosing as monotherapy and in combination with darabxrasib or cetuximab over time as applicable
Measured: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Half-Life of RMC-5127 and daraxonrasib
Elimination Half-Life (t1/2) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and t1/2 of daraxonrasib in combination with RMC-5127 over time as applicable
Measured: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Objective Response Rate (ORR)
ORR per response evaluation criteria in solid tumors (RECIST) v1.1
Measured: Up to approximately 3 years
Duration of Response (DOR)
DOR per RECIST v1.1
Measured: Up to approximately 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start8 Jan 2026
- Primary completionApr 2028 (estimated)
- Study completionOct 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-small Cell Lung Cancer (NSCLC)Studies of the same condition, open and under way.
- More trials run by Revolution Medicines, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 574 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Revolution Medicines, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07349537
- Sponsor's protocol ID
- RMC-5127-001
- Status last verified
- Sep 2026
- First submitted
- 9 Jan 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- ClinicalTrials.gov ID
- NCT07349537
- Acronym / sponsor ID
- RMC-5127-001
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC
- Keywords
- Advanced Solid Tumors, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC, Colorectal Cancer, CRC, Lung Cancer, Non-small Cell Lung Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 574 participants (estimated)
- Lead sponsor
- Revolution Medicines, Inc.Industry (pharma, biotech, devices)
- Study start
- 8 Jan 2026 (actual)
- Primary completion
- Apr 2028 (estimated)
- Study completion
- Oct 2028 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Detailed description
This is an open-label, multicenter, Phase 1/1b study of RMC-5127 in adults with advanced KRAS G12V-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of three arms: RMC-5127 monotherapy arm, RMC-5127 plus daraxonrasib combination arm, and RMC-5127 plus cetuximab combination arm. All arms consist of two parts: Part 1- dose exploration and Part 2- dose expansion. Both parts of the monotherapy arm may include Food Effect Cohorts.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Arm A: RMC-5127 Monotherapy | Experimental | Drug: RMC-5127Dose Escalation and Dose Expansion |
| Arm B: RMC-5127 + Daraxonrasib Combination | Experimental | Drug: RMC-5127, Drug: daraxonrasibDose Escalation and Dose Expansion |
| Arm C: RMC-5127 + Cetuximab Combination | Experimental | Drug: RMC-5127, Drug: cetuximabDose Escalation and Dose Expansion |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Pathologically documented, locally advanced or metastatic KRAS G12V-mutated solid tumor malignancy.
- Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
- Measurable per RECIST v1.1
Key exclusion criteria (5 listed)
- Primary central nervous system (CNS) tumors
- Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors).
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to receiving study drug(s).
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RMC-5127oral tablets | Drug | Arm A: RMC-5127 Monotherapy, Arm B: RMC-5127 + Daraxonrasib Combination, Arm C: RMC-5127 + Cetuximab Combination |
| daraxonrasiboral tablets | Drug | Arm B: RMC-5127 + Daraxonrasib Combination |
| cetuximabIV infusion | Drug | Arm C: RMC-5127 + Cetuximab Combination |
Primary outcome
Number of patients with adverse events (AEs)
Time frame: Up to approximately 3 years
Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5
Changes in vital signs
Time frame: Up to approximately 3 years
Number of patients with changes from baseline in vital signs
Changes in electrocardiogram (ECG) test values
Time frame: Up to approximately 3 years
Number of patients with changes from baseline in ECG test values
Changes in clinical laboratory test values
Time frame: Up to approximately 3 years
Number of patients with changes from baseline in clinical laboratory test values
Dose Limiting Toxicities
Time frame: Up to 28 days
Number of patients with dose limiting toxicities
7 secondary outcomes
Cmax concentrations of RMC-5127 and daraxonrasib
Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Tmax concentration of RMC-5127 and daraxonrasib
Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
AUC concentrations of RMC-5127 and daraxonrasib
Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Ratio of accumulation of RMC-5127
Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Half-Life of RMC-5127 and daraxonrasib
Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)
Objective Response Rate (ORR)
Time frame: Up to approximately 3 years
Duration of Response (DOR)
Time frame: Up to approximately 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Sep 2026.
Related trials for Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing RMC-5127, daraxonrasib and cetuximab in people with Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), run by Revolution Medicines, Inc. at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Revolution Medicines Study Director (1-844-2-REVMED, medinfo@revmed.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with adverse events (AEs) (time frame: Up to approximately 3 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.